FarmaKeio Custom Compounding, a pioneering pharmaceutical company, announced the acquisition of its latest location in Conway. This new facility marks a significant step in FarmaKeio’s mission to support the healthcare revolution by offering personalized compounded medications and excellent service to patients and practitioners nationwide.
The new facility is worth $2.29 million, and the company plans to generate 74 new jobs in the area.
“Today marks a momentous occasion for FarmaKeio as we proudly inaugurate our new Custom Compounding facility in Conway,” said Dan DeNeui, CEO of FarmaKeio. “This state-of-the-art facility signifies our unwavering commitment to personalized patient care. We are excited about the possibilities this facility brings and are optimistic about its potential to further enhance our ability to positively impact patient lives.”
FarmaKeio Custom Compounding already has a headquarters located in Richardson, Texas and has established a presence in the South. This new facility will provide additional space not only for its services and product lines, but also for research, testing, and development. The facility spans 16,000 square feet and features state-of-the-art compounding and laboratory equipment, ample office space, large production areas for both sterile and non-sterile work, and a warehouse for storage.
“Congratulations to FarmaKeio on the acquisition of its newest facility in Arkansas and congratulations to the team in Conway for securing this major investment,” said Governor Sarah Huckabee Sanders. “In my administration, we’re doing everything we can to make announcements like this regular by cutting taxes, investing in education, and building up a robust workforce.”
FarmaKeio Custom Compounding has expanded its production volume of compounded hormone medications and in-demand peptide medications, which will allow the company to reach more markets. This new facility empowers patients to receive tailored medications that are specifically designed for their individual needs, as hormone imbalances and specific medical conditions often require personalized therapies to achieve optimal results. FarmaKeio Custom Compounding compounds medications to exact dosages, eliminates allergens, and offers alternative delivery methods, ensuring patients can experience personalized treatments for enhanced outcomes and improved quality of life.
“FarmaKeio Custom Compounding is a fast-growing company, and the State of Arkansas is proud to be the home for their next location,” said Clint O’Neal, executive director of the Arkansas Economic Development Commission. “Congratulations to the City of Conway, the Conway Development Corporation, and local stakeholders on this exciting new announcement.”
Looking ahead, FarmaKeio Pharmacy Network plans to expand the facility to accommodate a second location for FarmaKeio Outsourcing, a 503B FDA-registered facility known for its patented triamcinolone pellet formulation.
“As the fastest growing city in Arkansas, we welcome another fast-growing company to the city,” said Conway Mayor Bart Castleberry. “We thank FarmaKeio Custom Compounding for choosing Conway and for adding to the diverse array of job opportunities for our people.”
“Congratulations to FarmaKeio on the facility purchase in Conway to meet increasing demand for their products and services,” said Faulkner County Judge Allen Dodson. “A growing company with a culture of innovation in pharmaceuticals and custom compounding is welcomed in Faulkner County. We are excited about their investment in our community.”
FarmaKeio has opened a new Custom Compounding facility, continuing their commitment to compounding medications, improving healthcare, and prioritizing patient solutions.
“We are excited to welcome FarmaKeio to Conway,” said Brad Lacy, president and CEO of the Conway Area Chamber of Commerce and the Conway Development Corporation. “Our diverse local economy has always been a strength of the community and region. FarmaKeio’s decision to locate here adds to that diversity and further strengthens our growing manufacturing sector.”
